NCT05810051 · ClinicalTrials.gov record · last posted 2026-01-20
Exercise and Coronary Microvascular Disease
Study acronym: ExerciseCMD
StatusActive, Not Recruiting
PhaseNot applicable
Started2023-07-31
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 20, 2026 (before its estimated April 15, 2026 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
Exercise CMD is a prospective single-center, open-label, parallel arms randomized controlled trial.
This trial aims to assess the impact of cardiac rehabilitation on top of optimal medical therapy on patient-reported outcomes in subjects with coronary microvascular disease and non-obstructive coronary artery disease.
Patients will undergo a microvascular assessment using bolus thermodilution techniques and those with criteria for microvascular angina (IMR ≥ 25) will be invited to participate.
Patients will be randomized in a 1:1 ratio to either optimal medical therapy (OMT) or OMT plus a program of cardiac rehabilitations (CR).
After randomization, spiro-ergometry and a SAQ-19 will be performed in all patients. Medical therapy will be standardized in both arms and the CR group will follow 36 sessions of the personalized physical training program of cardiac rehabilitation.
Approximately 204 subjects (102 in each group) will be included at one site (OLV Aalst, Belgium).
Clinical Follow-Up will be planned at 4 months. Patients with CCTA performed in standard of care will be invited for control CCTA 6 +/- 1 month after the invasive procedure.
Amendment record
4 amendments on the ClinicalTrials.gov record
This ClinicalTrials.gov record has been amended 4 times since 2023-03-30; most recent amendment 2026-01-16. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history.
See every version on ClinicalTrials.gov ↗
2026-01-16
Status change Recruiting→Active, Not Recruitingv4
2023-11-27
Status change Not Yet Recruiting→Recruitingv2
| NCT Number |
NCT05810051 |
| Lead Sponsor |
CoreAalst BV
Collaborators: Abbott Medical Devices |
| Conditions |
Coronary Microvascular Disease |
| Enrollment |
204 participants |
| Start Date |
2023-07-31 |
| Primary Completion |
2026-04-15 (estimated) |
| Study Completion |
2027-10-15 (estimated) |
| Updated on ClinicalTrials.gov |
2026-01-20 |